Just wondering here. Like quite a few people who have held this stock, I've been bemused by the FDA's attitudes and actions in response to both the obvious potential of Leronlimab and the mishandled trials by CYDY/Amarex.

Even lately, it's taken the FDA an unconscionably long time to help Dr. Jay put together a protocol for the Colorectal cancer trial. Have they been dragging their feet (still)?

Perhaps this good result can go a long way toward winning over the agency -- or even putting pressure on it to let Leronlimab prove itself in OTHER indications.
Maybe this result will be the snowball that gathers weight as it rolls.

Okay, now I sound like MGK. But you get what I mean.